Navigation Links
Eisai Inc. Announces Non-Exclusive Licensing Agreement with Generic Drug Manufacturer to Provide Generic Version of donepezil HCl 23 mg
Date:8/29/2013

WOODCLIFF LAKE, N.J., Aug. 29, 2013 /PRNewswire/ -- Eisai Inc. announced that the company has recently entered into a non-exclusive licensing agreement in the United States with a manufacturer of generic pharmaceuticals that grants certain rights, including the right to market and offer for sale a generic version of donepezil hydrochloride 23 mg and a non-exclusive license to Eisai Intellectual Property covering donepezil hydrochloride 23 mg, including U.S. Patent No. 8,481,565. This agreement applies to the United States only.

(Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO)

About Eisai Inc.
At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., our passionate commitment to patient care is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at www.eisai.com/US

Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as a global demand chain organization that includes manufacturing facilities in Maryland and North Carolina. Eisai's global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs. Media InquiriesInvestor InquiriesMarcia Diljak

Alex ScottEisai Inc.

Eisai Inc.(201) 746-2236

(201) 746-2177


'/>"/>
SOURCE Eisai Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Eisai Launches New Website Providing Employers with Educational Resource for Obesity Management
2. FDA Grants Orphan Drug Status To Eisais Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
3. For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders Opinions Indicate that AbbVie/Eisais Humira Has the Best Clinical Profile Among Key Marketed Therapies
4. Eisai USA Foundation to Donate $1 Million to the Conquer Cancer Foundation of the American Society of Clinical Oncology
5. Eisai To Sponsor 7th Annual National Walk For Epilepsy To Help Raise Epilepsy Awareness
6. Lynn Kramer, MD, Appointed Chief Clinical Officer of Eisai Product Creation Systems
7. FDA Grants Orphan Drug Status To Eisais Lenvatinib
8. Eisai Oncology to Present New Research on Eribulin at 35th Annual San Antonio Breast Cancer Symposium
9. Eisai USA Foundation to Donate $100,000 to the Hurricane Sandy New Jersey Relief Fund, $50,000 to the American Red Cross
10. Epilepsia Publishes Results From Two Studies Of Eisais Perampanel
11. Shaji Procida Appointed Vice President and Chief Financial Officer of Eisai Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ALTO, Calif. , Jan. 19, 2017   ... research, is excited to announce that the first ... Cancer Biology  (RP:CB) have been published in eLife ... this project represents the first practical evaluation of ... result in reproducible studies. Unlike other assessments of ...
(Date:1/19/2017)... Marks E-QURE , s 3 ... agreements in Israel and Argentina ... billion global market ... devices for the treatment of advanced wound care, announced today it signed a ... Colombia for the Company,s patented Bio-electrical Signal Therapy device ("BST Device"), ...
(Date:1/19/2017)... The drug delivery technology market is projected ... 1,179.20 billion in 2016, at a CAGR of 7.2% ... diseases, increasing demand for biologics, technological advancements, and new ... this market. Whereas, self-administration & home care and rising ... opportunities for players operating in this market. On the ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... ... examination of how God handles sin, including how to let go of lingering guilt and ... ten long years has been waiting to release this powerful insight about forgiveness that the ... the Lord for over twenty years, and he has been preaching and teaching the Word ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Land of More and More”: ... issue of world hunger, and shares the simple and achievable answer. “The Land of ... member of the Fairview Missionary Church in Angola, Indiana where he works with the ...
(Date:1/19/2017)... ... January 19, 2017 , ... Wells ... facility enhancement of their 503A compounding pharmacy located in Ocala, Florida. , ... physicians and patients throughout the United States for high-quality human anti-aging and ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... telemedicine solutions, has recently unveiled impressive transportable capabilities with their iMedHD2™ Portable ... is an extension to RMT technology that delivers HD, dynamic, streaming ultrasound images ...
(Date:1/19/2017)... ... January 19, 2017 , ... MB Business Capital, ... $11,250,000 senior credit facility to Sunrise, Florida-based Management Health Systems, LLC, dba MedPro ... facilitate a recapitalization of MedPro led by Harren Equity Partners. Brightwood Capital ...
Breaking Medicine News(10 mins):